European stocks rise: Democratic control of US Congress and Novo Nordisk surge

The news indicates that Novo Nordisk (NVO) posted a strong jump, with European equities broadly rising. The price closed at 40.22, up 3.97%, just below the SMA20 (40.27) but above the SMA50 (39.36). RSI14 at 57.3 remains far from overbought territory, with momentum neutral-to-positive. Although the MACD line is below its signal line (0.27 vs 0.35), the price trading close to its short-term averages suggests that news-driven buying interest could support an upward move within 1-3 days. Nevertheless, caution is warranted given the weak MACD signal and SMA20 resistance.

The news headline is mainly about European markets and Novo Nordisk; its direct impact on GOOGL is limited. Democratic control in the US Congress could increase expectations for technology regulation, which is a mildly negative factor for large tech stocks. On the technical side, RSI at 36 is weak but near oversold territory, MACD is negative and the price is just below the SMA20 and significantly below the SMA50; short-term momentum is weak. Therefore, the 1-3 day outlook is neutral with a slight downward bias; an additional catalyst is needed for a clear direction.

The DAX is trading at 26,248 with strong momentum, up 1.63% over the past 24 hours, and is trading above both its SMA20 and SMA50. The RSI stands at 68.4, approaching the overbought threshold, while the MACD remains positive above its signal line. A favorable news flow is supporting risk appetite, including Democratic control in the US Congress and a jump in Novo Nordisk. However, the elevated RSI level points to limited upside potential and the risk of profit-taking in the near term. Accordingly, the 1-3 day outlook is assessed as moderately positive, with cautious optimism.